Literature DB >> 16720833

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Rodrigo Martino1, Rocio Parody, Takahiro Fukuda, Johan Maertens, Koen Theunissen, Aloysius Ho, Ghulam J Mufti, Nicolaus Kroger, Arnold R Zander, Dominik Heim, Monika Paluszewska, Dominik Selleslag, Katerina Steinerova, Per Ljungman, Simone Cesaro, Anna Nihtinen, Catherine Cordonnier, Lourdes Vazquez, Monica López-Duarte, Javier Lopez, Rafael Cabrera, Montserrat Rovira, Stefan Neuburger, Oliver Cornely, Ann E Hunter, Kieren A Marr, Hans Jürgen Dornbusch, Hermann Einsele.   

Abstract

In this retrospective study, we analyzed the outcomes of 129 patients who underwent an allogeneic hematopoietic stem cell transplantation (allo-HSCT) and had a history of probable or proven invasive aspergillosis (IA), of whom 57 (44%) received a reduced-intensity conditioning (RIC). Overall, 27 patients with IA progressed after the allo-HSCT (cumulative incidence [CumInc] at 2 years, 22%). The variables that increased the 2-year CumInc of IA progression were (1) longer duration of neutropenia after transplantation; (2) advanced status of the underlying disease; and (3) less than 6 weeks from start of systemic anti-Aspergillus therapy and the allo-HSCT. In addition, (4) conventional myeloablative conditioning increased the risk of progression early after transplantation (before day 30) only, while 3 variables increased the risk beyond day 30 were (5) cytomegalovirus disease; (6) bone marrow or cord blood as source of stem cells; and (7) grades II to IV acute graft-versus-host disease (GVHD). A risk model for progression was generated, defined as low (0-1 risk factors, 6% incidence), intermediate (2-3 risk factors, 27% incidence), or high risk (> or = 3 risk factors, 72% incidence [P < .001]). These findings may help in the interpretation and design of future studies on secondary prophylaxis of IA after an allo-HSCT.

Entities:  

Mesh:

Year:  2006        PMID: 16720833      PMCID: PMC1895522          DOI: 10.1182/blood-2006-03-008706

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

2.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

Authors:  Luis Ostrosky-Zeichner; Barbara D Alexander; Daniel H Kett; Jose Vazquez; Peter G Pappas; Fumihiro Saeki; Paul A Ketchum; John Wingard; Robert Schiff; Hiroshi Tamura; Malcolm A Finkelman; John H Rex
Journal:  Clin Infect Dis       Date:  2005-07-21       Impact factor: 9.079

3.  Impact of previous aspergillosis on the outcome of bone marrow transplantation.

Authors:  F Offner; C Cordonnier; P Ljungman; H G Prentice; D Engelhard; D De Bacquer; F Meunier; B De Pauw
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

4.  Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories.

Authors:  Arlo Upton; Anja Gugel; Wendy Leisenring; Ajit Limaye; Barbara Alexander; Randall Hayden; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.

Authors:  Kieren A Marr; Michel Laverdiere; Anja Gugel; Wendy Leisenring
Journal:  Clin Infect Dis       Date:  2005-05-05       Impact factor: 9.079

6.  Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study.

Authors:  Johan Maertens; Axel Glasmacher; Dominik Selleslag; Angela Ngai; Desmond Ryan; Melissa Layton; Arlene Taylor; Carole Sable; Nicholas Kartsonis
Journal:  Clin Infect Dis       Date:  2005-05-17       Impact factor: 9.079

7.  Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.

Authors:  Rodrigo Martino; José A Pérez-Simón; Estela Moreno; José M Queraltó; Dolores Caballero; Marivi Mateos; Anna Sureda; Consuelo Cañizo; Salut Brunet; Javier Briones; Lourdes Vazquez; Ana Clopés; Jesús F San Miguel; Jorge Sierra
Journal:  Biol Blood Marrow Transplant       Date:  2005-06       Impact factor: 5.742

8.  Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings.

Authors:  Sunita Sharma; Hassan F Nadrous; Steve G Peters; Ayalew Tefferi; Mark R Litzow; Marie-Christine Aubry; Bekele Afessa
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

9.  Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies.

Authors:  M Weisser; C Rausch; A Droll; M Simcock; P Sendi; I Steffen; C Buitrago; S Sonnet; A Gratwohl; J Passweg; U Fluckiger
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

10.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

View more
  30 in total

1.  Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.

Authors:  Jean El Cheikh
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Prophylaxis of invasive fungal diseases in patients with hematologic disorders.

Authors:  Corrado Girmenia
Journal:  Haematologica       Date:  2010-10       Impact factor: 9.941

3.  Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study.

Authors:  Caroline Even; Sylvie Bastuji-Garin; Yosr Hicheri; Cécile Pautas; Francoise Botterel; Sébastien Maury; Ludovic Cabanne; Stéphane Bretagne; Catherine Cordonnier
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

4.  Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Saurabh Chhabra; Kwang Woo Ahn; Zhen-Huan Hu; Sandeep Jain; Amer Assal; Jan Cerny; Edward A Copelan; Andrew Daly; Zachariah DeFilipp; Shahinaz M Gadalla; Robert Peter Gale; Siddhartha Ganguly; Betty K Hamilton; Gerhard Carl Hildebrandt; Jack W Hsu; Yoshihiro Inamoto; Abraham S Kanate; H Jean Khoury; Hillard M Lazarus; Mark R Litzow; Sunita Nathan; Richard F Olsson; Attaphol Pawarode; Olle Ringden; Jacob M Rowe; Ayman Saad; Bipin N Savani; Harry C Schouten; Sachiko Seo; Nirav N Shah; Melhem Solh; Robert K Stuart; Celalettin Ustun; Ann E Woolfrey; Jean A Yared; Edwin P Alyea; Matt E Kalaycio; Uday Popat; Ronald M Sobecks; Wael Saber
Journal:  Blood Adv       Date:  2018-11-13

5.  Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients.

Authors:  Catherine Cordonnier; Montserrat Rovira; Johan Maertens; Oliver A Cornely; Per Ljungman; Hermann Einsele
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

6.  How I transplant a patient with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-08-26       Impact factor: 22.113

7.  Secondary antifungal prophylaxis in hematological malignancies in a tertiary medical center.

Authors:  Axia Song; Dong-Lin Yang; Yong Huang; Er-Lie Jiang; Zhang-Song Yan; Jia-Lin Wei; Mei Wang; Qiao-Ling Ma; Yi He; Rong-Li Zhang; Wei-Hua Zhai; Si-Zhou Feng; Ming-Zhe Han
Journal:  Int J Hematol       Date:  2010-12-03       Impact factor: 2.490

8.  Caspofungin as secondary antifungal prophylaxis and subsequent maintenance antifungal prophylaxis therapy in hematological malignancy patients.

Authors:  Mingjuan Liu; Yan Li; Xiaoli Zhao; Yongqing Zhang; Bing Zhai; Qingyi Zhang; Lijun Wang; Yu Zhao; Honghua Li; Quanshun Wang; Chunji Gao; Wenrong Huang; Li Yu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

9.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Authors:  Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Luca Malcovati; Emanuele Angelucci; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Stefano Guidi; Barbarella Lucarelli; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Cristiana Pascutto; Rosi Oneto; Laura Pirolini; Renato Fanin; Alberto Bosi
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

Review 10.  Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation?

Authors:  John R Wingard
Journal:  Best Pract Res Clin Haematol       Date:  2012-10-23       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.